Principal Financial Group Inc. lowered its holdings in AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) by 1.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 242,352 shares of the medical instruments supplier’s stock after selling 3,025 shares during the quarter. Principal Financial Group Inc. owned approximately 0.62% of AngioDynamics worth $2,506,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Raymond James & Associates raised its position in shares of AngioDynamics by 15.3% in the 1st quarter. Raymond James & Associates now owns 19,420 shares of the medical instruments supplier’s stock worth $201,000 after acquiring an additional 2,581 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of AngioDynamics in the 4th quarter worth approximately $706,000. Lapides Asset Management LLC raised its position in shares of AngioDynamics by 39.7% in the 1st quarter. Lapides Asset Management LLC now owns 298,200 shares of the medical instruments supplier’s stock worth $3,083,000 after acquiring an additional 84,700 shares in the last quarter. Victory Capital Management Inc. increased its position in AngioDynamics by 47.3% during the 4th quarter. Victory Capital Management Inc. now owns 4,261,474 shares of the medical instruments supplier’s stock valued at $58,680,000 after buying an additional 1,369,109 shares in the last quarter. Finally, Engineers Gate Manager LP increased its position in AngioDynamics by 1,139.0% during the 4th quarter. Engineers Gate Manager LP now owns 121,437 shares of the medical instruments supplier’s stock valued at $1,672,000 after buying an additional 111,636 shares in the last quarter. Institutional investors own 90.52% of the company’s stock.
Wall Street Analysts Forecast Growth
ANGO has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price objective on AngioDynamics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, July 13th. StockNews.com initiated coverage on AngioDynamics in a research report on Thursday, August 17th. They set a “hold” rating for the company.
AngioDynamics Stock Down 3.7 %
ANGO stock opened at $7.73 on Tuesday. AngioDynamics, Inc. has a twelve month low of $7.69 and a twelve month high of $22.88. The company has a quick ratio of 1.29, a current ratio of 1.95 and a debt-to-equity ratio of 0.13. The firm has a market cap of $306.65 million, a PE ratio of -5.86 and a beta of 0.61. The business has a 50 day moving average of $8.94 and a 200 day moving average of $9.92.
AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its earnings results on Wednesday, July 12th. The medical instruments supplier reported $0.02 EPS for the quarter, hitting analysts’ consensus estimates of $0.02. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $90.73 million. AngioDynamics had a negative return on equity of 0.61% and a negative net margin of 15.48%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.01 EPS. On average, research analysts forecast that AngioDynamics, Inc. will post -0.32 EPS for the current fiscal year.
AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.
- Five stocks we like better than AngioDynamics
- What is the Hang Seng index?
- MarketBeat Week in Review – 8/28 – 9/1
- How to Invest in Solar Energy
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- What is a Secondary Public Offering? What Investors Need to Know
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.